The SEZ “Technopolis “Moscow” for 170 million rubles will launch the production of drugs for mesotherapy and biorevitalization

Subsidiary of the group of companies “Mesopharm” – LLC “Mesoformula” – will invest 170 million rubles in the production of drugs for professional and medical cosmetology. The plant will be built on the site of the special economic zone (SEZ) Technopolis Moscow, and its launch is scheduled for the third quarter of 2022.
“The plant for the production of cosmetic products will be built on the site of the SEZ in Pechatniki and will occupy an area of ​​more than 1.5 thousand square meters. m. It is planned that by 2024 the company will invest over 170 million rubles in the project and create about 50 highly qualified jobs” said Alexander Prokhorov, head of the Moscow Investment and Industrial Policy Department.

The company became a SEZ resident in March 2021. Among the products of the new resident are injectable preparations for cosmetology (preparations for mesotherapy and biorevitalization). The new enterprise will allow bringing the level of localization of production up to 85%, as well as increasing production volumes to meet consumer demands.

According to the state register of medical devices and organizations engaged in the production and manufacture of medical devices, Mesopharm LLC is the holder of registration certificates for biorevitalizants Nucleospire Revitalizing complex A, Nucleospire DNA-RNA 1%, Hydro Line, Hydro Line Extra, Estetic Form, MesoHydral, Hair X, GAG complex, ADN restart. According to the registration documents, the production of products is carried out by “Pharmzashchita” of the FMBA of Russia in Khimki and LLC “Pharma Gen” in St. Petersburg.

According to SPARK-Interfax, OOO Mesoformula was registered in 2015 in Moscow. The main activity is the production of materials used for medical purposes. The company is 95% owned by OOO Mesopharm, 2.55% – by Nadezhda Kapleva, who is the general director of the company, and 2.45% – by Irina Karelina. The company’s revenue in 2020 amounted to 67.9 million rubles, net profit – 11.9 million rubles. The owner of Mesopharm LLC is Svetlana Zakharchenko.

At the end of 2018, the share of the “gray” segment of the cosmetic services market in physical terms decreased in three categories of injectable products at once: from 25.2% to 24.8% for fillers, from 31.5% to 25% – for biorevitalizants, in the category “Botulinum toxins” the share of “grayness” has receded from 24% to 6%.

In April 2020, most players in the aesthetic medical services market expressed their fear that the situation with the coronavirus pandemic, a “collapse” of demand, could threaten the industry with plunging into a “gray” zone: specialists left without work will join the ranks of “homeworkers”, the share of counterfeit circulation will increase, and due to the jump in exchange rates, legitimate imports will rise in price, which will lead to an increase in prices for cosmetic services.